FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020164117> ?p ?o ?g. }

• W2020164117 endingPage "373" @default.
• W2020164117 startingPage "365" @default.
• W2020164117 abstract "The Liquemin in Myocardial Infarction During Thrombolysis With Saruplase (LIMITS) study was instituted to evaluate and characterize the effect of a prethrombolytic heparin bolus (5,000 IU) on the efficacy and safety of saruplase in patients with acute myocardial infarction.Heparin has been used after thrombolytic therapy for acute myocardial infarction to prevent reocclusion of the infarct-related artery.The study was designed as a randomized, parallel-group, double-blind, multicenter trial. Patients were treated within 6 h of onset of symptoms with either a bolus of 5,000 IU of heparin (Liquemin) (n = 56, HSH group) or placebo (n = 62, PSH group) before thrombolytic treatment with saruplase given as a 20-mg bolus followed by an infusion of 60 mg over 60 min. Thirty minutes after completion of thrombolysis, an intravenous heparin infusion was administered for 5 days. Before coronary angiography was performed at 6 to 12 h after start of lysis, an additional bolus of 5,000 IU heparin was given to all patients. End points studied were patency of the infarct-related artery, changes in the hemostatic system and bleeding complications.In the HSH group (heparin-saruplase-heparin), 78.6% of patients had an open infarct-related vessel (Thrombolysis in Myocardial Infarction [TIMI] flow grade 2 or 3) compared with 56.5% in the PSH group (placebo-saruplase-heparin) (intention-to-treat analysis, p = 0.01). No significant difference was observed between the two groups with regard to changes in fibrinogen and fibrin/fibrinogen degradation products. A total of eight bleeding complications (14.3%) were observed in the HSH group and five (8.1%) in the PSH group; no cerebrovascular event occurred, and no allergic reaction was reported. A total of 12 patients died during the hospital stay, 3 in the HSH group (5.4%) and 9 in the PSH group (14.5%).In acute myocardial infarction, the administration of a heparin bolus before thrombolytic therapy with saruplase is associated with a significantly higher patency at angiography 6 to 12 h after the start of thrombolysis without any appreciable increase in risk of bleeding." @default.
• W2020164117 created "2016-06-24" @default.
• W2020164117 creator A5006158915 @default.
• W2020164117 creator A5006828536 @default.
• W2020164117 creator A5020514673 @default.
• W2020164117 creator A5023563685 @default.
• W2020164117 creator A5044329053 @default.
• W2020164117 creator A5048754657 @default.
• W2020164117 creator A5054889861 @default.
• W2020164117 creator A5063688985 @default.
• W2020164117 creator A5064457021 @default.
• W2020164117 creator A5084340012 @default.
• W2020164117 creator A5087661676 @default.
• W2020164117 date "1995-08-01" @default.
• W2020164117 modified "2023-10-07" @default.
• W2020164117 title "Thrombolysis with recombinant unglycosylated single-chain urokinase-type plasminogen activator (saruplase) in acute myocardial infarction: influence of heparin on early patency rate (LIMITS study)" @default.
• W2020164117 cites W1596397105 @default.
• W2020164117 cites W1877774943 @default.
• W2020164117 cites W1977967610 @default.
• W2020164117 cites W1980123039 @default.
• W2020164117 cites W1982450495 @default.
• W2020164117 cites W1983192419 @default.
• W2020164117 cites W1983527519 @default.
• W2020164117 cites W1988058782 @default.
• W2020164117 cites W2032989095 @default.
• W2020164117 cites W2044191826 @default.
• W2020164117 cites W2049956362 @default.
• W2020164117 cites W2054251417 @default.
• W2020164117 cites W2064206690 @default.
• W2020164117 cites W2069680463 @default.
• W2020164117 cites W2072410496 @default.
• W2020164117 cites W2075535659 @default.
• W2020164117 cites W2077866784 @default.
• W2020164117 cites W2078324852 @default.
• W2020164117 cites W2085869479 @default.
• W2020164117 cites W2101310081 @default.
• W2020164117 cites W2164042498 @default.
• W2020164117 cites W2164771213 @default.
• W2020164117 cites W2169518571 @default.
• W2020164117 cites W2170309901 @default.
• W2020164117 cites W2245823081 @default.
• W2020164117 cites W2337057096 @default.
• W2020164117 cites W3025057188 @default.
• W2020164117 cites W3170680033 @default.
• W2020164117 cites W4235858444 @default.
• W2020164117 cites W4251417417 @default.
• W2020164117 doi "https://doi.org/10.1016/0735-1097(95)80008-5" @default.
• W2020164117 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7608436" @default.
• W2020164117 hasPublicationYear "1995" @default.
• W2020164117 type Work @default.
• W2020164117 sameAs 2020164117 @default.
• W2020164117 citedByCount "36" @default.
• W2020164117 countsByYear W20201641172012 @default.
• W2020164117 countsByYear W20201641172014 @default.
• W2020164117 countsByYear W20201641172016 @default.
• W2020164117 countsByYear W20201641172020 @default.
• W2020164117 crossrefType "journal-article" @default.
• W2020164117 hasAuthorship W2020164117A5006158915 @default.
• W2020164117 hasAuthorship W2020164117A5006828536 @default.
• W2020164117 hasAuthorship W2020164117A5020514673 @default.
• W2020164117 hasAuthorship W2020164117A5023563685 @default.
• W2020164117 hasAuthorship W2020164117A5044329053 @default.
• W2020164117 hasAuthorship W2020164117A5048754657 @default.
• W2020164117 hasAuthorship W2020164117A5054889861 @default.
• W2020164117 hasAuthorship W2020164117A5063688985 @default.
• W2020164117 hasAuthorship W2020164117A5064457021 @default.
• W2020164117 hasAuthorship W2020164117A5084340012 @default.
• W2020164117 hasAuthorship W2020164117A5087661676 @default.
• W2020164117 hasBestOaLocation W20201641171 @default.
• W2020164117 hasConcept C126322002 @default.
• W2020164117 hasConcept C142724271 @default.
• W2020164117 hasConcept C164705383 @default.
• W2020164117 hasConcept C204787440 @default.
• W2020164117 hasConcept C27081682 @default.
• W2020164117 hasConcept C2776825266 @default.
• W2020164117 hasConcept C2776892390 @default.
• W2020164117 hasConcept C2777557582 @default.
• W2020164117 hasConcept C2777995511 @default.
• W2020164117 hasConcept C2779036427 @default.
• W2020164117 hasConcept C2779581417 @default.
• W2020164117 hasConcept C2779679481 @default.
• W2020164117 hasConcept C42219234 @default.
• W2020164117 hasConcept C43376680 @default.
• W2020164117 hasConcept C500558357 @default.
• W2020164117 hasConcept C71924100 @default.
• W2020164117 hasConceptScore W2020164117C126322002 @default.
• W2020164117 hasConceptScore W2020164117C142724271 @default.
• W2020164117 hasConceptScore W2020164117C164705383 @default.
• W2020164117 hasConceptScore W2020164117C204787440 @default.
• W2020164117 hasConceptScore W2020164117C27081682 @default.
• W2020164117 hasConceptScore W2020164117C2776825266 @default.
• W2020164117 hasConceptScore W2020164117C2776892390 @default.
• W2020164117 hasConceptScore W2020164117C2777557582 @default.
• W2020164117 hasConceptScore W2020164117C2777995511 @default.
• W2020164117 hasConceptScore W2020164117C2779036427 @default.
• W2020164117 hasConceptScore W2020164117C2779581417 @default.
• W2020164117 hasConceptScore W2020164117C2779679481 @default.
• W2020164117 hasConceptScore W2020164117C42219234 @default.

• next